Olaris and Labcorp Expand Access to myOLARIS KTdx

Olaris, Inc. and Labcorp announced a commercial collaboration to support commercialization and broaden clinical access to myOLARIS®-KTdx (KTdx), per a press release distributed via PRNewswire on June 22, 2026. The release describes KTdx as a first-of-its-kind, non-invasive, urine-based laboratory developed test for surveillance of kidney graft injury, and states the test is intended to detect borderline rejection, subclinical and clinical rejection, and polyomavirus associated nephropathy (PVAN). Per the press release, the collaboration will integrate KTdx more directly into clinical workflows across the United States and combine Olaris' metabolomics and machine-learning diagnostics with Labcorp's national laboratory infrastructure and commercialization capabilities. The release includes a statement from Marcia Eisenberg, Ph.D., CSO at Labcorp: "As Labcorp builds on its capabilities in transplant diagnostics, we're proud to work with Olaris to help bring solutions like KTdx to more patients and providers nationwide."

For practitioners: urine-based, non-invasive assays for transplant surveillance leverage molecular and metabolomic signals that can complement biopsy and blood-based monitoring. Companies integrating metabolomics with machine learning often focus on feature selection, batch-effect control, and cross-site normalization as key technical challenges before clinical-scale rollouts. Broader laboratory network distribution typically raises demands on assay reproducibility and end-to-end sample handling pipelines, which in turn affects model maintenance and retraining requirements.

Commercial partnerships between diagnostics developers and national laboratory providers frequently accelerate clinician access and payer routing, reducing logistical friction for collection, testing, and reporting. For data scientists and clinical informaticists, increased test volumes across diverse sites can supply much-needed real-world data for external validation, calibration, and post-market performance monitoring, while also exposing models to greater pre-analytic variability.

Observers should track peer-reviewed validation studies and regulatory or payer coverage updates that reference KTdx, the volume and geographic distribution of tests processed through Labcorp's network, and any public technical documentation from Olaris about analytic pipelines, pre-analytic controls, or model performance metrics over time. Monitoring those outputs will clarify the assay's clinical utility and implications for ML model lifecycle management.